ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, Kao S, Yip PY, Mersiades AJ, Nagrial A, Bray V, Peters G, Parakh S, Garg K, Li BT, McKay M, O'Byrne K, John T, Gill AJ, Molloy MP, Solomon BJ, Pavlakis N.
Itchins M, et al. Among authors: molloy mp.
JTO Clin Res Rep. 2024 Jul 8;5(9):100703. doi: 10.1016/j.jtocrr.2024.100703. eCollection 2024 Sep.
JTO Clin Res Rep. 2024.
PMID: 39309618
Free PMC article.